AxoGen (AXGN) Set to Announce Earnings on Thursday

AxoGen (NASDAQ:AXGN) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect AxoGen to post earnings of ($0.10) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.11. The business had revenue of $42.92 million for the quarter, compared to analyst estimates of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative return on equity of 22.38%. On average, analysts expect AxoGen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Price Performance

Shares of AXGN stock opened at $6.66 on Tuesday. AxoGen has a 1-year low of $3.45 and a 1-year high of $10.83. The company has a current ratio of 2.89, a quick ratio of 2.14 and a debt-to-equity ratio of 0.71. The firm’s 50-day simple moving average is $8.27 and its 200-day simple moving average is $7.40.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 price objective on shares of AxoGen in a report on Friday, January 19th. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th.

Insider Activity at AxoGen

In related news, CEO Karen L. Zaderej sold 39,280 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $301,670.40. Following the transaction, the chief executive officer now owns 1,124,565 shares in the company, valued at $8,636,659.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Karen L. Zaderej sold 39,280 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $301,670.40. Following the transaction, the chief executive officer now owns 1,124,565 shares in the company, valued at $8,636,659.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Erick Wayne Devinney sold 4,578 shares of AxoGen stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total transaction of $35,159.04. Following the sale, the insider now owns 165,661 shares in the company, valued at approximately $1,272,276.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,201 shares of company stock worth $928,054. Company insiders own 7.21% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.